Recce share price jumps 15% on positive data

The Recce share price jumped nearly 15% higher today on news out of the company before being sold off to a 6% gain at the time of writing.

| More on:
increasing bar graph created from medical tablets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price traded nearly 15% higher this morning after the company announced positive oral data.

What new data has Recce released?

Recce Pharmaceuticals released an announcement earlier today which highlighted positive oral data for the company's new antibiotic RECCE 435. The data relates to an independent efficacy study that assessed the oral dose-dependent efficacy of RECCE 435 in an animal model. According to the announcement, the data showed positive efficacy against Helicobacter plylori (H. pylori) in rats treated with RECCE 435.

H. pylori is a Gram-negative and antibiotic-resistant bacteria that infects the lining of the stomach and upper intestine. The bacteria was recently added by the United States Food and Drug Administration as a pathogen that has the potential to pose a threat to public health and has an unmet medical need.

The study involved treating 3 groups with varying doses of RECCE 435, with dose-dependent efficacy reported at all doses which resulted in significant reduction in bacterial load. The company's management noted that the new data is encouraging and endorses further study into synthetic antibiotics in the treatment of deadly infections. As a result, Recce Pharmaceuticals is in discussion with world leading H. pylori experts to assess a potential commercial pathway.

What does Recce do?

Recce Pharmaceuticals is an Australian based biopharmaceutical company that aims at developing and commercialising new classes of synthetic anti-infectives to treat antibiotic resistant superbugs and emerging viral pathogens. The company's antibiotics are unique as their potency does not diminish with repeated use, which is a failure of existing antibiotics used to treat resistant superbugs.

RECCE 327 is the company's lead candidate which has been developed for the treatment of blood infections and sepsis that results from E.coli and S. aureus bacteria. In addition to the aforementioned RECCE 435, RECCE 529 is another candidate from Recce Pharamceuticals that is designed as an antiviral compound.  

Earlier last month, Reece Pharmaceuticals announced that the company had entered an agreement with US-based precision medicine company, Path BioAnalytics, for the study of its RECCE 327 and RECCE 529 antibiotics against SARS-CoV-2, which is the strain of coronavirus that causes COVID-19. In addition, the company noted that its candidate RECCE 327 has been accepted into the SARS-CoV-2 screening program between the CSIRO and Doherty Institute.

The Recce share price

Following its initial surge, the Recce share price has been sold off and is currently trading at $1.255 which is a 6.4% increase for the day. This came after the share price hit an intra-day high of $1.355 immediately following the announcement. The Recce share price is 269% up in year-to-date trading.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »